Login to Your Account



Financings Roundup

FANG Bites Off $24M Series B; Gradalis Ovarian Trial Advances

By Randy Osborne
Staff Writer

Thursday, January 3, 2013
Investor enthusiasm for Gradalis Inc.'s autologous vaccine platform, Furin-ANd-GMCSF (FANG), boosted what began as a $10 million or so Series B round to an amount more than twice that much, and the firm will use the $24 million to move the Phase II ovarian cancer therapy along while expanding manufacturing capabilities.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription